INGREZZA (valbenazine) Patient Assistance Program
Don’t let the high cost of brand specialty VMAT2 inhibitor therapy disrupt your treatment. We help eligible patients access Ingrezza (valbenazine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Ingrezza (valbenazine) is FDA-approved for the treatment of tardive dyskinesia in adults and for chorea associated with Huntington's disease in adults. It is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor with once-daily dosing.
- Without assistance, Ingrezza costs commonly run approximately $8,500–$10,500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Ingrezza for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Ingrezza in the U.S. as of 2026. The other VMAT2 inhibitor approved for tardive dyskinesia and Huntington's chorea is deutetrabenazine (Austedo). For Huntington's chorea, generic tetrabenazine is available at lower cost (with more frequent dosing and more side effects).
What Is Ingrezza Prescription Assistance Program?
The Ingrezza Prescription Assistance Program is a manufacturer-sponsored initiative that provides Ingrezza at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for tardive dyskinesia and Huntington’s chorea patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, psychiatry/neurology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Ingrezza costs roughly $8,500–$10,500/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$10,200 | Save ~$10,130/mo |
| CVS Pharmacy | ~$10,500 | Save ~$10,430/mo |
| Walmart | ~$9,000 | Save ~$8,930/mo |
| Costco | ~$8,800 | Save ~$8,730/mo |
Specialty Pharmacy | ~$9,200 | Save ~$9,130/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Ingrezza Prescription Program?
The Patient Assistance Program is free to apply for and provides Ingrezza at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ingrezza:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $8,500–$10,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Ingrezza assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Ingrezza Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Ingrezza:
Ingrezza (valbenazine) is a once-daily oral selective VMAT2 inhibitor used to treat tardive dyskinesia and chorea in Huntington’s disease. It has a simpler dosing structure than deutetrabenazine — no titration after the first month — and was the first VMAT2 inhibitor specifically approved for tardive dyskinesia.
How Ingrezza Works:
Tardive dyskinesia is a chronic movement disorder caused by long-term exposure to dopamine-blocking medications, leading to receptor supersensitivity and involuntary movements. Valbenazine treats this by selectively inhibiting VMAT2, which depletes dopamine in presynaptic vesicles and reduces its release at the synapse. This highly selective action calms involuntary movements with a relatively favorable side-effect profile compared to older agents. Significant reductions in tardive dyskinesia symptoms are typically observed within 6 to 8 weeks.
Form and use:
Ingrezza is typically started at 40 mg once daily and increased to the recommended target dose of 80 mg once daily after one week. Lower daily doses of 40 mg or 60 mg may be appropriate for specific patients, such as CYP2D6 poor metabolizers or those taking strong CYP3A4/CYP2D6 inhibitors. The medication can be taken with or without food. Additionally, a sprinkle formulation is available for patients who experience difficulty swallowing capsules.
Generic availability:
As of 2026, generic Ingrezza is not available in the United States. Deutetrabenazine (Austedo or Austedo XR) is the only other VMAT2 inhibitor approved for treating tardive dyskinesia. For Huntington’s chorea, generic tetrabenazine is available at a lower cost. However, generic tetrabenazine requires three-times-daily dosing and carries a higher risk of depression, sedation, and Parkinsonism than Ingrezza or Austedo.
Warnings:
Ingrezza carries a boxed warning for depression and suicidality, but only when used for Huntington’s disease chorea, not for tardive dyskinesia. Additional warnings include QTc prolongation, parkinsonism, hepatic impairment requiring dose adjustment, and somnolence or sedation. It is contraindicated for use with concurrent MAOIs or reserpine. Furthermore, strong CYP3A4 inducers should be avoided as they reduce valbenazine levels.
FAQ (Frequently Asked Questions)
How Much Does Ingrezza Cost Without Insurance?
Ingrezza costs approximately $8,500–$10,500 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Ingrezza at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Ingrezza Different From Austedo?
Both are VMAT2 inhibitors for tardive dyskinesia (and Huntington’s chorea). Ingrezza (valbenazine) — once daily, simpler dosing, starts at 40 mg and increases to 80 mg after 1 week. Austedo (deutetrabenazine) — IR is twice daily requiring titration over weeks; Austedo XR is once daily. Both are effective; choice often depends on insurance coverage, preferred dosing schedule, and individual response. Both are expensive without assistance.
Should I Continue My Antipsychotic While On Ingrezza?
Generally yes, if you need the antipsychotic for psychiatric stability. Ingrezza treats TD that has developed from chronic antipsychotic exposure — it does not address the underlying psychiatric condition. Discontinuing the antipsychotic can worsen psychiatric symptoms. Your psychiatrist may, in some cases, switch you to a different antipsychotic with lower TD risk (such as clozapine or quetiapine), but this requires careful management.
Will My TD Get Better Or Just Be Controlled?
Ingrezza substantially reduces TD severity for many patients. Whether TD ever truly resolves depends on the patient and the duration/severity of prior dopamine-blocker exposure. Many patients have major improvement that allows return to function. Ingrezza is generally continued long-term to maintain control of TD.
Are There Drug Interactions I Should Know About?
Yes. Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) raise valbenazine levels — dose reduction needed. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort) substantially reduce levels — avoid. Strong CYP2D6 inhibitors raise the active metabolite. MAOIs are contraindicated. Tell every prescriber and pharmacist about Ingrezza.
Can I Get Ingrezza Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria
What If My Application Is Denied?
If denied, we explore alternatives — switching to Austedo (with its own PAP), generic tetrabenazine for Huntington’s chorea (much cheaper but more side effects), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the National Alliance on Mental Illness (NAMI), Huntington’s Disease Society of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Ingrezza, our team may be able to help you access assistance programs designed to make brand specialty VMAT2 inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.